Cargando…
Update on the second-line treatment of Helicobacter pylori infection: a narrative review
A standard bismuth quadruple therapy, a fluoroquinolone-containing triple (or quadruple) therapy or a proton pump inhibitor (PPI)-amoxicillin high-dose dual therapy has been recommended as a second-line treatment for Helicobacter pylori infection by the Maastricht VI/Florence Consensus Report. The m...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478561/ https://www.ncbi.nlm.nih.gov/pubmed/37675247 http://dx.doi.org/10.1177/17562848231192750 |
_version_ | 1785101379926228992 |
---|---|
author | Shih, Chih-An Shie, Chang-Bih Tai, Wei-Chen Chuah, Seng-Kee Lee, Hsi-Chang Hsu, Ping-I |
author_facet | Shih, Chih-An Shie, Chang-Bih Tai, Wei-Chen Chuah, Seng-Kee Lee, Hsi-Chang Hsu, Ping-I |
author_sort | Shih, Chih-An |
collection | PubMed |
description | A standard bismuth quadruple therapy, a fluoroquinolone-containing triple (or quadruple) therapy or a proton pump inhibitor (PPI)-amoxicillin high-dose dual therapy has been recommended as a second-line treatment for Helicobacter pylori infection by the Maastricht VI/Florence Consensus Report. The major shortcoming of levofloxacin-amoxicillin triple therapy is low cure rate for eradicating levofloxacin-resistant strains. With the rising prevalence of levofloxacin-resistant strains, levofloxacin-amoxicillin triple therapy cannot reliably achieve a high eradication rate for second-line treatment of H. pylori infection in most countries now. The present article aims to review current second-line eradication regimens with a per-protocol eradication rate exceeding 85% in most geographic areas. Recently, a novel tetracycline-levofloxacin quadruple therapy consisting of a PPI, bismuth, tetracycline, and levofloxacin for rescue treatment of H. pylori infection has been developed. The new therapy achieved a higher per-protocol eradication rate than levofloxacin-amoxicillin triple treatment in a randomized controlled trial (98% versus 69%). Additionally, the tetracycline-levofloxacin quadruple therapy also exhibits a higher eradication rate than amoxicillin-levofloxacin quadruple therapy. High-dose dual PPI-amoxicillin therapy is another novel second-line treatment for H. pylori infection. The new therapy can achieve an eradication rate of 89% by per-protocol analysis for the second-line treatment in Taiwan. Recently, levofloxacin-based sequential quadruple therapy and potassium-competitive acid blocker have also been applied in the second-line treatment of H. pylori infection. A meta-analysis revealed that a vonoprazan-based regimen has significant superiority over a PPI-based regimen for second-line H. pylori eradication therapy. In conclusion, the eradication rate of levofloxacin-amoxicillin triple therapy is suboptimal in the second-line treatment of H. pylori infection now. Currently, a standard bismuth quadruple therapy (tetracycline-metronidazole quadruple therapy), a tetracycline-levofloxacin quadruple therapy, an amoxicillin-levofloxacin quadruple therapy, a levofloxacin-based sequential quadruple therapy or a high-dose PPI-amoxicillin dual therapy is recommended for the second-line treatment of H. pylori infection. |
format | Online Article Text |
id | pubmed-10478561 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-104785612023-09-06 Update on the second-line treatment of Helicobacter pylori infection: a narrative review Shih, Chih-An Shie, Chang-Bih Tai, Wei-Chen Chuah, Seng-Kee Lee, Hsi-Chang Hsu, Ping-I Therap Adv Gastroenterol Helicobacter pylori Infection – pathogenesis, management and prevention A standard bismuth quadruple therapy, a fluoroquinolone-containing triple (or quadruple) therapy or a proton pump inhibitor (PPI)-amoxicillin high-dose dual therapy has been recommended as a second-line treatment for Helicobacter pylori infection by the Maastricht VI/Florence Consensus Report. The major shortcoming of levofloxacin-amoxicillin triple therapy is low cure rate for eradicating levofloxacin-resistant strains. With the rising prevalence of levofloxacin-resistant strains, levofloxacin-amoxicillin triple therapy cannot reliably achieve a high eradication rate for second-line treatment of H. pylori infection in most countries now. The present article aims to review current second-line eradication regimens with a per-protocol eradication rate exceeding 85% in most geographic areas. Recently, a novel tetracycline-levofloxacin quadruple therapy consisting of a PPI, bismuth, tetracycline, and levofloxacin for rescue treatment of H. pylori infection has been developed. The new therapy achieved a higher per-protocol eradication rate than levofloxacin-amoxicillin triple treatment in a randomized controlled trial (98% versus 69%). Additionally, the tetracycline-levofloxacin quadruple therapy also exhibits a higher eradication rate than amoxicillin-levofloxacin quadruple therapy. High-dose dual PPI-amoxicillin therapy is another novel second-line treatment for H. pylori infection. The new therapy can achieve an eradication rate of 89% by per-protocol analysis for the second-line treatment in Taiwan. Recently, levofloxacin-based sequential quadruple therapy and potassium-competitive acid blocker have also been applied in the second-line treatment of H. pylori infection. A meta-analysis revealed that a vonoprazan-based regimen has significant superiority over a PPI-based regimen for second-line H. pylori eradication therapy. In conclusion, the eradication rate of levofloxacin-amoxicillin triple therapy is suboptimal in the second-line treatment of H. pylori infection now. Currently, a standard bismuth quadruple therapy (tetracycline-metronidazole quadruple therapy), a tetracycline-levofloxacin quadruple therapy, an amoxicillin-levofloxacin quadruple therapy, a levofloxacin-based sequential quadruple therapy or a high-dose PPI-amoxicillin dual therapy is recommended for the second-line treatment of H. pylori infection. SAGE Publications 2023-09-04 /pmc/articles/PMC10478561/ /pubmed/37675247 http://dx.doi.org/10.1177/17562848231192750 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Helicobacter pylori Infection – pathogenesis, management and prevention Shih, Chih-An Shie, Chang-Bih Tai, Wei-Chen Chuah, Seng-Kee Lee, Hsi-Chang Hsu, Ping-I Update on the second-line treatment of Helicobacter pylori infection: a narrative review |
title | Update on the second-line treatment of Helicobacter pylori infection: a narrative review |
title_full | Update on the second-line treatment of Helicobacter pylori infection: a narrative review |
title_fullStr | Update on the second-line treatment of Helicobacter pylori infection: a narrative review |
title_full_unstemmed | Update on the second-line treatment of Helicobacter pylori infection: a narrative review |
title_short | Update on the second-line treatment of Helicobacter pylori infection: a narrative review |
title_sort | update on the second-line treatment of helicobacter pylori infection: a narrative review |
topic | Helicobacter pylori Infection – pathogenesis, management and prevention |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478561/ https://www.ncbi.nlm.nih.gov/pubmed/37675247 http://dx.doi.org/10.1177/17562848231192750 |
work_keys_str_mv | AT shihchihan updateonthesecondlinetreatmentofhelicobacterpyloriinfectionanarrativereview AT shiechangbih updateonthesecondlinetreatmentofhelicobacterpyloriinfectionanarrativereview AT taiweichen updateonthesecondlinetreatmentofhelicobacterpyloriinfectionanarrativereview AT chuahsengkee updateonthesecondlinetreatmentofhelicobacterpyloriinfectionanarrativereview AT leehsichang updateonthesecondlinetreatmentofhelicobacterpyloriinfectionanarrativereview AT hsupingi updateonthesecondlinetreatmentofhelicobacterpyloriinfectionanarrativereview |